Safety and Efficacy of Ruxolitinib in Patients With HNSCC and High NLR Treated With Pembrolizumab - The Phase 2 InflammaSTOP Trial (clinicaltrials.gov) - Sep 26, 2026 - P2 | N=66 | Not yet recruiting | Sponsor: University Hospital, Basel, Switzerland
New P2 trial • Head and Neck Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • PD-L1
|